Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T-cell therapy effective for r/r B-cell lymphoma of the GI tract

Publish date:: April 13, 2020

Key clinical point: CAR T-cell therapy was effective for gastrointestinal relapsed/refractory B-cell lymphoma.

Major finding: An objective response was achieved in 10/14 patients, with 7 achieving a complete response.

Study details: Open-label, single-center study of infusion of anti-CD22 and anti-CD19 CAR T cells in 14 patients with r/r B-cell malignancies involving the GI tract.

Disclosures: The study was funded by the National Science Foundation of China. The authors reported they had no conflicts of interest.

Citation:

Zheng C et al. Cytotherapy. 2020;22:166-71.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,